SOUTH SAN FRANCISCO, Calif., April 13, 2023 (GLOBE NEWSWIRE) — Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that it will participate in four upcoming investor conferences. Any available webcasts will be posted to the…Read More
Allogene Therapeutics Announces Participation in Four Upcoming Investor Conferences
